The results not only demonstrate that the FABP‐3 might serve as a predictor for the clinician to prevent the progression to CKD for these high‐risked patients but also suggest that FABP‐3 itself may be a pharmacological target for preventing renal damage. This evidence concerns the gene FABP3 and chronic kidney disease.